Experts in Steinert disease (DM1) have just produced recommendations concerning the use of mexiletine, a class I anti-arrhythmic agent which may improve the lack of muscle relaxation (myotonia):
- three neurologists and five cardiologists took part in the working group,
- data from the literature and experience gained from prescribing this drug off-label were taken into account,
- the known risk of cardiac complications with this treatment requires a cardiological assessment prior to any long-term prescription, followed by regular monitoring,
- a decision-making algorithm is now available to all potential prescribers.
